<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
<journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
<journal-id journal-id-type="publisher-id">abd</journal-id>
<journal-title-group>
<journal-title>Anais Brasileiros de Dermatologia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0365-0596</issn>
<issn pub-type="epub">1806-4841</issn>
<publisher>
<publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29924239</article-id>
<article-id pub-id-type="pmc">6001077</article-id>
<article-id pub-id-type="doi">10.1590/abd1806-4841.20186972</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Continuing Medical Education</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Tuberous sclerosis complex: review based on new diagnostic
criteria<xref ref-type="fn" rid="fn1">*</xref></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-3357-1013</contrib-id>
<name>
<surname>Portocarrero</surname>
<given-names>Larissa Karine Leite</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="c1"></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-5920-8186</contrib-id>
<name>
<surname>Quental</surname>
<given-names>Klícia Novais</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7077-8553</contrib-id>
<name>
<surname>Samorano</surname>
<given-names>Luciana Paula</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-8596-1999</contrib-id>
<name>
<surname>de Oliveira</surname>
<given-names>Zilda Najjar Prado</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-2910-7330</contrib-id>
<name>
<surname>Rivitti-Machado</surname>
<given-names>Maria Cecília da Matta</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label> Outpatient Clinic of Pediatric Dermatology, Hospital das
Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP),
São Paulo (SP), Brazil. </aff>
<aff id="aff2">
<label>2</label> Department of Dermatology, Hospital das Clínicas, Faculdade
de Medicina, Universidade de São Paulo (HC-FMUSP), São Paulo (SP),
Brazil. </aff>
<author-notes>
<corresp id="c1"><bold>Mailing address:</bold> Larissa Karine Leite Portocarrero. E-mail:
<email>larissakleite@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<season>May-Jun</season>
<year>2018</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<season>May-Jun</season>
<year>2018</year>
</pub-date>
<volume>93</volume>
<issue>3</issue>
<fpage>323</fpage>
<lpage>331</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial No Derivative License, which
permits unrestricted non-commercial use, distribution, and reproduction in
any medium provided the original work is properly cited and the work is not
changed in any way.</license-p>
</license>
</permissions>
<abstract>
<p>Tuberous sclerosis complex is a multisystemic, autosomal dominant genetic
disorder with complete penetrance, that can evolve with hamartomas in multiple
organs, such as skin, central nervous system, kidney and lung. Due to the wide
phenotypic variability, the disease is often not recognized. Tuberous sclerosis
complex affects one in 10,000 newborns and most patients are diagnosed during
the first 15 months of life. The diagnostic criteria for tuberous sclerosis were
reviewed in 2012, at the second International Tuberous Sclerosis Complex
Consensus Conference. The diagnosis is based on genetic criteria, by the
identification of inactivating pathogenic mutation of tumor suppressor genes
TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary,
cardiac and neurological manifestations. The treatment of tuberous sclerosis
complex consists, mainly, in management of the symptoms caused by hamartomas and
in prevention of organ failure. Multidisciplinary approach is recommended, in
order to obtain better clinical outcomes.</p>
</abstract>
<kwd-group>
<kwd>Diagnosis</kwd>
<kwd>Hamartoma</kwd>
<kwd>Sirolimus</kwd>
<kwd>Tuberous Sclerosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Tuberous sclerosis complex (TSC) is a multisystemic neurocutaneous genetic condition
with autosomal dominant inheritance, characterized by hamartomas that affect
multiple organs, including skin, central nervous system, heart, lungs, and kidney.
It is also known as epiloia or Pringle-Bourneville phacomatosis, and was initially
described in the 19<sup>th</sup> century by Virchow and Von Recklinghausen, who
identified hamartomas in the brain and heart during the necropsy of patients with
seizures and mental retardation. However, the correlation between the cutaneous
manifestations with other clinical symptoms and the description of the syndrome were
made by Bourneville in the beginning of the 20<sup>th</sup> century. Years after,
Campbell in 1905 and Vogt three years later established the triad that characterizes
TSC, which is mental retardation, epilepsy and Pringle type of sebaceous adenoma
(angiofibroma).<sup><xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r2">2</xref></sup></p>
<p>Diagnostic criteria for tuberous sclerosis were firstly established in
1998.<sup><xref ref-type="bibr" rid="r3">3</xref></sup> In 2012, in the
second International Tuberous Sclerosis Complex Consensus Conference held in
Washington, these criteria were reviewed with the aim of presenting recommendations
for the diagnosis, surveillance and management of TSC patients.<sup><xref ref-type="bibr" rid="r3">3</xref></sup></p>
<p>The condition affects one in every 6,000 to 10,000 individuals and can affect both
sexes and all ethnic groups equally. It has a great phenotypical variability, which
can sometimes make its recognition difficult.<sup><xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r5">5</xref></sup></p>
</sec>
<sec>
<title>EPIDEMIOLOGY AND ETIOPATHOGENESIS</title>
<p>TSC occurs due to the deletion, rearrangement and inactivating mutation of tumor
suppressor genes TSC1 or TSC2, that lead to abnormal proteins hamartin and tuberin,
codified in the loci 9p34 and 16p13, respectively.<sup><xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r6">6</xref></sup> The role of
these genes consists in the regulation of cellular growth through the
phosphatidylinositol 3-kinase signaling pathway, inhibiting the mammalian target of
rapamycin (mTOR).<sup><xref ref-type="bibr" rid="r7">7</xref></sup> The complex
hamartin/tuberin is an important inhibitor of tumor growth. These proteins suppress
the activity of the mTOR pathway, responsible for cellular proliferation and
inhibition of cellular apoptosis. In TSC patients, changes in these proteins lead to
a permanent activation of the mTOR pathway, and therefore to the formation of
hamartomas in multiple organs. Familial cases of the condition are due to germline
mutations and, despite being able to be transmitted hereditarily, 70% of TSC
patients are the result of somatic mutations, configuring sporadic cases.<sup><xref ref-type="bibr" rid="r1">1</xref></sup> Studies demonstrate that changes in
the TSC2 gene are more common and lead to a more severe neurological impairment when
compared to TSC due to mutations in TSC1.<sup><xref ref-type="bibr" rid="r5">5</xref>,<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r9">9</xref></sup> Cases of familial transmission result in mild to
moderate disease, sometimes not fulfilling all diagnostic criteria and have a higher
frequency of changes in the TSC1 gene.</p>
</sec>
<sec>
<title>CLINICAL MANIFESTATIONS</title>
<p>Most patients affected by TSC seek medical attention due to seizures or skin
lesions.<sup><xref ref-type="bibr" rid="r10">10</xref></sup> TSC is a
condition with variable expression and complete penetrance. Both sexes are equally
affected but women can have more marked signs.<sup><xref ref-type="bibr" rid="r1">1</xref></sup> Cutaneous manifestations represent the most common findings
observed in TSC patients, even though there are some affected individuals with no
cutaneous involvement. Neurological and renal complications are the main cause of
morbidity and mortality associated to the condition.</p>
<sec>
<title>Cutaneous manifestations</title>
<p>Skin lesions are detected in all ages and affect more than 90% of TSC
patients.<sup><xref ref-type="bibr" rid="r10">10</xref></sup></p>
<p>Among the cutaneous manifestations, hypopigmented macules are present in 90% of
the cases and are usually found at birth, making it possible to suspect the
diagnosis at an early age. When the cutaneous lesions are associated to other
clinical findings, the definitive and early diagnosis of the syndrome can be
made.<sup><xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r5">5</xref>,<xref ref-type="bibr" rid="r6">6</xref></sup> The most
typical macules are hypopigmented and have a leaf shape, round in one end and
pointed in the other, the so called “ash-leaf”. They are usually larger than
5mm. Over the years, new macules can appear, including smaller, round
hypopigmented macules known as “confetti” lesions. In adulthood, “ash-leaf”
lesions tend to become milder, with repigmentation and sometimes they can
disappear. Clinically, “confetti” lesions and guttate leukoderma are difficult
to differentiate, however, the former appear during childhood and can be
asymmetrically distributed over the body.<sup><xref ref-type="bibr" rid="r1">1</xref></sup></p>
<p>Facial angiofibromas are observed in 83 to 90% of cases and usually appear in the
first decade of life, around the 3<sup>rd</sup> or 4<sup>th</sup> year of life.
The number of lesions can increase during adolescence, becoming stable during
adulthood. They are characterized by papules that affect mainly the malar, nasal
dorsum, nasolabial fold, forehead and chin areas, ranging in color from normal,
when they have more fibrous tissue, to violaceous, where blood vessels
predominate.<sup><xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r11">11</xref></sup> Even though they are usually
asymptomatic, angiofibromas can bleed spontaneously, impair eye sight and affect
the quality of life due to the aesthetic disfiguration.<sup><xref ref-type="bibr" rid="r12">12</xref></sup> In some patients, these
lesions become confluent, causing marked disfiguration.<sup><xref ref-type="bibr" rid="r13">13</xref></sup></p>
<p>Connective tissue nevi are normal-colored or brown plaques that can be present at
birth or appear during childhood and adolescence. Among these lesions, some are
called shagreen patches when located on the lumbosacral region, with the orange
peel appearance and histologic features similar to other collagenomas found on
the trunk. Fibrous cephalic plaque, considered the most specific TSC lesion, is
present in 25% of cases, and is more commonly found on one side of the forehead
but it can also be seen in other areas of the face and scalp.<sup><xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r14">14</xref></sup></p>
<p>Ungual fibroma or Koenen tumor are tumors observed later, usually after the
second decade of life and can progressively increase in size. It has
predilection for females and for the toes and generally can cause longitudinal
ridging on the nails when they affect the ungual matrix.<sup><xref ref-type="bibr" rid="r1">1</xref></sup></p>
<p>In the oral cavity, the most common lesions are pits on the teeth enamel and
gingival fibromas. Dental pits are more common in TSC patients compared to the
general population and need a through clinical examination for their diagnosis,
being not seen many of the times. Gingival fibromas are seen in 20 to 50% of the
patients, most during adulthood, and can be normal-colored or violaceous,
usually on the anterior gingiva.<sup><xref ref-type="bibr" rid="r3">3</xref></sup></p>
</sec>
<sec>
<title>Renal manifestations</title>
<p>Renal angiomyolipomas are extremely common benign tumors in TSC patients,
observed in 80% of cases. They progressively enlarge from the first years of
life, with an obvious growth during adolescence or early adulthood and stop
enlarging in the elderly in about 30% of cases.<sup><xref ref-type="bibr" rid="r15">15</xref>,<xref ref-type="bibr" rid="r16">16</xref></sup> They
are responsible for a marked morbidity and mortality in TSC patients, despite
most of them being asymptomatic. When there are clinical manifestations from
these tumors, hematuria and loss of kidney function are highlighted, as well as
risk of hemorrhage for tumors larger than 30mm. Besides angiomyolipomas, TSC
patients have a higher incidence of multiple renal cysts when compared to the
general population, due to the mutation in the TSC1 and TSC2 genes.<sup><xref ref-type="bibr" rid="r15">15</xref>,<xref ref-type="bibr" rid="r16">16</xref></sup></p>
<p>There are reports of TSC associated to the renal cell carcinoma in children and
young adults, considered to be a rare manifestation, with an overall incidence
of around 1 to 2%, what makes the diagnosis challenging. Many times, it is
difficult to distinguish it from angiomyolipomas with sparse fat tissue through
conventional imaging studies. If this diagnosis is suspected, a biopsy with
histology is recommended to avoid invasive surgical procedures. There is little
information in the literature about its prognosis and response to conventional
treatments.<sup><xref ref-type="bibr" rid="r17">17</xref>,<xref ref-type="bibr" rid="r18">18</xref></sup></p>
</sec>
<sec>
<title>Pulmonary manifestations</title>
<p>Replacement of alveolar tissue by cysts and proliferation of the smooth muscle,
known as lymphangioleiomyomatosis, progressively affect the pulmonary function
in 40% of the patients.<sup><xref ref-type="bibr" rid="r15">15</xref></sup> It
affects mainly adult females, being rare the symptomatic cases in men. The most
common signs and symptoms are cough, dyspnea, hemoptysis and pneumothorax.</p>
</sec>
<sec>
<title>Cardiac manifestations</title>
<p>Rhabdomyoma is the most frequent cardiac tumor, appearing early in the fetus and
newborn, around between the 20<sup>th</sup> to 30<sup>th</sup> weeks of
gestation, more commonly seen in the ventricle wall.<sup><xref ref-type="bibr" rid="r8">8</xref></sup> The repercussions of these tumors vary according
to the location and number of lesions. Most of the time they can be
asymptomatic, or evolve with cardiomegaly, murmurs, changes in the blood flow,
arrhythmias, non-immune hydrops and death. Among breastfeeding babies with
multiple cardiac rhabdomyomas, 80% or more have TSC. These lesions can be
identified from 22<sup>nd</sup> week of gestation. Most patients have an average
of three lesions, measuring approximately 3 to 25mm in size but isolated lesions
are also of diagnostic importance.<sup><xref ref-type="bibr" rid="r5">5</xref></sup> In the clinical course, these tumors usually involve
completely within the first years of life.<sup><xref ref-type="bibr" rid="r1">1</xref></sup></p>
</sec>
<sec>
<title>Neurological manifestations</title>
<p>The main neurological manifestation of TSC is epilepsy, which occurs in 70 to 90%
of the individuals with the condition and this is the sign that most frequently
leads to the diagnosis of the syndrome. Seizures usually start within the first
three years of life, typically as infantile spasms and focal seizures. However,
it is possible to find all types of seizures in TSC patients and in two thirds
of the cases there is initially focal refractory epilepsy.<sup><xref ref-type="bibr" rid="r19">19</xref></sup> Moreover, these patients
present a higher risk for other neurocognitive deficits such as manifestations
in the autism spectrum, mental retardation and mood disturbances.<sup><xref ref-type="bibr" rid="r15">15</xref></sup> Neuroimaging studies can show
cortical and subcortical tubers and migration lines in the white matter, these
being the manifestations responsible for cortical dysplasia.<sup><xref ref-type="bibr" rid="r19">19</xref></sup> Other findings include
subependymal nodules in the wall of the lateral ventricles and a third ventricle
in 80% of the cases that are usually asymptomatic; and also giant cell
subependymal astrocytomas, observed in 5 to 15% of TSC patients, which in turn
can lead to ventriculomegaly and hydrocephalus, resulting in marked morbidity
and mortality.<sup><xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r19">19</xref></sup> The disturbances in the autism spectrum, among
other behavioral problems, can be identified in 40% to 50% of the patients.
These have a prevalence of 75% of coexisting cognitive impairment and an
additional prevalence of 75% to 100% of concomitant epilepsy.<sup><xref ref-type="bibr" rid="r5">5</xref></sup> In addition, the term TAND
(tuberous sclerosis-associated neuropsychiatric disorders) was introduced to
illustrate all the biopsychosocial difficulties seen in patients with tuberous
sclerosis.<sup><xref ref-type="bibr" rid="r19">19</xref></sup> Some of
them include behavior changes, aggressiveness, anxiety, depressive mood, sleep
disorders, and learning difficulties. Changes in the neurodevelopment such as
attention deficit and hyperactivity are found in 30% to 40% of TSC
patients.<sup><xref ref-type="bibr" rid="r19">19</xref></sup></p>
</sec>
<sec>
<title>Ophthalmologic abnormalities</title>
<p>Retinal hamartoma can be present in 30% to 50% of patients and tends to be
bilateral and multiple, becoming apparent during infancy. In the majority of
patients, the lesions do not cause visual impairment. Patients can also present
hypopigmented macule in the retina, which corresponds to the hypopigmented
macules seen on the skin.</p>
</sec>
<sec>
<title>Liver abnormalities</title>
<p>Gastrointestinal manifestations are uncommon in TSC patients and rarely liver
angiomyolipomas can be found, which have a predilection for females.<sup><xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r20">20</xref></sup></p>
</sec>
</sec>
<sec>
<title>DIAGNOSIS AND FOLLOW-UP</title>
<p>The diagnostic criteria for tuberous sclerosis were reviewed in 2012, in the second
International Tuberous Sclerosis Complex Consensus Conference, after a meeting with
79 experts from 14 countries, with the objective of establishing recommendations for
the diagnosis, surveillance and management of TSC patients. Some changes were made
comparing to the previous criteria (1998),<sup><xref ref-type="bibr" rid="r3">3</xref></sup> being the most relevants the inclusion of genetic testing,
the refinement of the clinical criteria and the exclusion of probable
diagnosis.<sup><xref ref-type="bibr" rid="r3">3</xref></sup></p>
<p>According to the new genetic criterion, the identification of the pathogenic mutation
in TSC1 or TSC2 DNA is enough to establish the definitive diagnosis of TSC,
configuring an independent diagnostic criterion. Molecular testing yields a positive
result in 75% to 90% of TSC patients; in a significant fraction (10% to 25%),
conventional genetic testing did not identify the pathogenic mutation. Therefore, a
normal result in the molecular testing does not rule out TSC. However, if the
mutation is identified in an affected patient, genetic testing has a high predictive
value for the other family members.<sup><xref ref-type="bibr" rid="r3">3</xref></sup> The growing availability of molecular testing and the advent of
sophisticated technologies allowed genetics to become a great contributor for the
diagnosis of TSC. This new criterion facilitates diagnosis, especially in
breast-feeding babies who still have not fulfilled the diagnostic criteria based on
clinical manifestations. In countries where the analysis of the mutations is less
available, clinical criteria continue to be the main way of establishing the
diagnosis of tuberous sclerosis.<sup><xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r19">19</xref></sup></p>
<p>Clinical criteria are divided into major: hypopigmented macules (≥ 3, with at
least 5mm diameter), angiofibromas (≥ 3) or fibrous cephalic plaque, ungual
fibromas (≥ 2), <italic>shagreen</italic> patch, multiple retinal hamartomas,
cortical dysplasia, subependymal nodules, subependymal giant cell astrocytoma,
cardiac rhabdomyoma, lymphangioleiomyomatosis, angiomyolipomas (≥ 2); and
minor: “confetti” lesion, enamel pits (&gt; 3), intraoral fibroma (≥ 2),
retinal hypopigmented macule, multiple renal cysts and nonrenal hamartomas (<xref ref-type="table" rid="t1">Chart 1</xref>, <xref ref-type="fig" rid="f1">Figure
1</xref> and <xref ref-type="fig" rid="f2">2</xref>).<sup><xref ref-type="bibr" rid="r3">3</xref></sup> The definitive diagnosis is defined by the presence
of two major criteria or one major and two minor criteria. Probable diagnosis is
made with one major criteria or two or more minor.</p>
<table-wrap id="t1" orientation="portrait" position="float">
<label>Chart 1</label>
<caption>
<p>Clinical criteria for the diagnosis of tuberous sclerosis complex</p>
</caption>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col span="1" width="60%"/>
<col span="1" width="40%"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" style="background-color:#cfbed4">Major criteria</th>
<th align="left" colspan="1" rowspan="1" style="background-color:#cfbed4">Minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>1.</bold>
Hypomelanotic macules<break></break>(≥ 3,≥ 5mm in
diameter)</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>1.</bold>
"Confetti" skin lesions</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>2.</bold>
Angiofibromas (≥ 3) or<break></break>fibrous cephalic plaque</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>2.</bold> Dental
enamel pits (&gt; 3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>3.</bold> Ungual
fibromas (≥ 2)</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>3.</bold>
Intraoral fibroma (≥ 2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>4.</bold>
Shagreen patch</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>4.</bold>
Retinal achromic patch</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>5.</bold>
Multiple retinal hamartomas</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>5.</bold>
Multiple renal cysts</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>6.</bold>
Cortical dysplasia</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>6.</bold>
Nonrenal hamartomas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>7.</bold>
Subependymal nodules</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>8.</bold>
Subependymal giant cell<break></break>astrocytoma</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>9.</bold>
Cardiac rhabdomyoma</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>10.</bold>
Lymphangioleiomyomatosis</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"><bold>11.</bold>
Angiomyolipomas (≥ 2)</td>
<td align="left" colspan="1" rowspan="1" style="background-color:#cfbed4"> </td>
</tr>
</tbody>
</table>
</table-wrap>
<p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><bold>A</bold> - Fibrous cephalic plaque; <bold>B</bold> - Facial
angiofibromas; <bold>C</bold> - Intraoral fibroma; <bold>D</bold> -
Dental B enamel pits</p></caption><graphic xlink:href="abd-93-03-0323-g01"></graphic></fig>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>A</bold> - “Ash-leaf” hypopigmented macules; <bold>B</bold> -
Shagreen patch; <bold>C</bold> - Periungual fibroma (Koenen tumor)</p></caption><graphic xlink:href="abd-93-03-0323-g02"></graphic></fig>
</p>
<p>There are no specific symptoms for the diagnosis of TSC. However, there are clinical
presentations that can occur in the context of TSC that require further
investigation. Moreover, if the patient under investigation has one of the
biological parents with TSC, there is a 50% chance that the patient under
investigation has the condition. This 50% risk remains unchanged when multiple
siblings are affected.</p>
<p>Diagnostic suspicion of TSC comes from the antenatal detection of cardiac
rhabdomyomas; the post-natal identification of hypopigmented macules on the skin;
seizures in childhood, particularly with spasms; and presence or absence of
cognitive impairment during autism assessment. The International Tuberous Sclerosis
Complex Consensus recommends yearly screening for neuropsychiatric disorders and
when clinically indicated.<sup><xref ref-type="bibr" rid="r19">19</xref></sup></p>
<p>From the dermatologist point of view, a full dermatological examination is
recommended. Family history of at least three generations should be obtained, and
genetic testing should be considered in cases where there is suspicion of the
diagnosis or for family-planning. Dental and ophthalmological evaluations are also
recommended, including fundoscopy, to all individuals with the diagnosis of TSC in
search of hamartomas and retinal hypopigmented lesions. Complementary investigations
should be considered in children at the time of diagnosis and include brain magnetic
resonance, to evaluate tubercles, subependymal nodules or other intracranial
lesions; electroencephalogram, to evaluate the activity of subclinical seizure;
transthoracic echocardiogram, to investigate rhabdomyomas (particularly in patients
younger than three years of age) and electrocardiogram, to evaluate underlying
conduction defects. Imaging studies, including abdominal ultrasound, computed
tomography or magnetic resonance should be performed at the time of diagnosis,
regardless of age, to evaluate angiomyolipomas or renal cysts, being the abdominal
magnetic resonance the preferred method since many angiomyolipomas can be poor in
fat tissue and not visualized by the other methods. Pulmonary function tests and
high-resolution chest computed tomography for the investigation of
lymphangioleiomyomatosis are indicated for women with 18 years old or older and in
symptomatic men.<sup><xref ref-type="bibr" rid="r21">21</xref></sup></p>
</sec>
<sec>
<title>TREATMENT</title>
<p>TSC treatment consists, above all, of the management of the symptoms caused by
hamartomas and prophylactic measures to avoid loss of function of the affected
organ. Because it is a systemic disease, a multidisciplinary follow-up is mandatory,
with the need of assessment and follow-up in conjunction with teams of genetics,
neurology, ophthalmology, pneumology, nephrology, and odontology.<sup><xref ref-type="bibr" rid="r1">1</xref></sup></p>
<p>From the dermatological point of view, multiple descriptive or surgical treatments
were developed to decrease the development and remove facial angiofibromas such as
dermabrasion, surgical excision, electrocautery and laser. However, these procedures
tend to be uncomfortable for the patient, need to be repeated periodically to avoid
recurrence of the lesions and many times need to be associated to other therapeutic
methods in an attempt to optimize results.<sup><xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r13">13</xref></sup></p>
<p>For the treatment of facial angiofibromas with a predominantly vascular component,
intense pulsed light (IPL) has been shown particularly effective. Fibrous or
protruding lesions respond better to carbon dioxide laser resurfacing, although this
treatment also presents a higher risk for hypertrophic scarring.<sup><xref ref-type="bibr" rid="r22">22</xref></sup></p>
<p>Due to the progressive enlargement and recurrence of facial tumors, surgical
treatment can be postponed until after adolescence, when their growth is maximum.
Painful ungual fibromas can be surgically excised, cauterized or treated with laser,
however, recurrence is common.<sup><xref ref-type="bibr" rid="r1">1</xref></sup></p>
<p>In TSC patients, the mTOR protein is aberrantly activated in fibroblast -like cells
located in the dermis. These cells produce an epidermal growth factor, epiregulin,
that simulates cellular proliferation.<sup><xref ref-type="bibr" rid="r13">13</xref>,<xref ref-type="bibr" rid="r23">23</xref></sup> This
overproduction of cells along with angiogenesis result in the initial appearance and
continuous progression of facial angiofibromas throughout life.</p>
<p>After the discovery of the regulation of the mTOR pathway in the development of TSC
tumors and with the advent of the target therapy using mTORC1 inhibitors, some
promising studies have been highlighted, favoring the possibility of treating TSC
patients according to the physiopathogenesis of the condition. Rapamycin is a
natural macrolide isolated from <italic>Streptomyces hygroscopicus</italic> in 1965,
that binds specifically to mTOR, resulting in the inhibition of mTOR activity and
finally promoting the inhibition of cellular growth.<sup><xref ref-type="bibr" rid="r13">13</xref></sup> Rapamycin mTOR inhibitors and their derivative
everolimus have been studied in TSC patients since 2006 and are promising for the
treatment of multiple tumors including renal angiomyolipomas, giant cell
subependymal astrocytomas and lymphangioleiomyomatosis, with secondary benefits on
the cutaneous manifestations.<sup><xref ref-type="bibr" rid="r24">24</xref>-<xref ref-type="bibr" rid="r26">26</xref></sup></p>
<p>Randomized, double-blind, placebo-controlled clinical trials, EXIST-1 (efficacy and
safety of everolimus for subependymal giant cell astrocytomas - SEGAs - associated
with tuberous sclerosis complex) and EXIST-2 (everolimus for angiomyolipoma
associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis)
demonstrated beneficial effects of everolimus in both TSC manifestations.<sup><xref ref-type="bibr" rid="r27">27</xref>,<xref ref-type="bibr" rid="r28">28</xref></sup> These studies allowed the approval of everolimus by the
<italic>European Medicines Agency</italic> (EMA) and by the <italic>Food and
Drug Administration</italic> (FDA) for the treatment of adult patients with
renal angiomyolipoma associated to TSC and with risk of complications (based on the
size of the tumor, the presence of aneurysm and of multiple or bilateral tumors)
that did not need immediate surgery. Everolimus is also indicated for the treatment
of patients with SEGAs regardless of age, who require therapeutic intervention but
are not eligible for surgery.<sup><xref ref-type="bibr" rid="r29">29</xref></sup>
Either rapamycin or everolimus proved to reduce the severity of epilepsy in TSC
patients.<sup><xref ref-type="bibr" rid="r25">25</xref>,<xref ref-type="bibr" rid="r30">30</xref></sup> In Brazil, these drugs are
approved by the <italic>Agência Nacional de Vigilância
Sanitária</italic> (ANVISA) in patients with TSC with the following
indications/ everolimus for renal angiomyolipomas without indication of immediate
surgery (in patients over 18 years) and SEGA; and sirolimus for
lymphangioleiomyomatosis.<sup><xref ref-type="bibr" rid="r31"> 31</xref>,<xref ref-type="bibr" rid="r32">32</xref></sup></p>
<p>In regards to the cutaneous effects of mTOR inhibitors, in a retrospective study that
evaluated the response to sirolimus in 14 patients with lymphangioleiomyomatosis,
they were also submitted to serial photographic documentation of the facial
angiofibromas before, during and after the treatment, associated to microscopic and
molecular studies of these lesions before and during the administration of
sirolimus. The study revealed that cutaneous tumors not only improved after
treatment with systemic sirolimus but also maintained the improvement for at least
64 months of treatment.<sup><xref ref-type="bibr" rid="r31">31</xref></sup> In a
similar way to other studies that also evaluated the secondary cutaneous response to
systemic sirolimus indicated for renal tumors, facial angiofibromas responded more
favorably to the treatment than ungual fibromas and shagreen patches. Therefore, it
is possible that the antiangiogenic properties of sirolimus are responsible for the
apparent superior benefit in highly vascularized cutaneous tumors. Unexpectedly,
angiofibromas did not worsen after discontinuation of the treatment in this study.
This is contrary to the progression of cutaneous and visceral tumors reported in
previous studies after ceasing systemic therapy.<sup><xref ref-type="bibr" rid="r31">31</xref>,<xref ref-type="bibr" rid="r32">32</xref></sup></p>
<p>Current guidelines limit the use of oral mTORC1 inhibitors for the treatment of TSC
cutaneous lesions for individuals that are not eligible to surgical approaches and
whose skin lesions have a severe risk of recurrent and extensive
hemorrhages.<sup><xref ref-type="bibr" rid="r5">5</xref></sup></p>
<p>However, the oral treatment with mTOR inhibitors is associated to an increased risk
of infections, stomatitis being the most frequent, acne, amenorrhea and laboratory
abnormalities. Considerations of these effects are important, since treatment with
mTOR inhibitors should be long lasting because withdrawal of the medication results
in a rebound growth of the tumor (SEGA, renal angiomyolipoma, cardiac rhabdomyoma
and cutaneous lesions) in the majority of the patients.<sup><xref ref-type="bibr" rid="r33">33</xref></sup></p>
<p>A small series of cases reported benefits using topical preparations of rapamycin in
facial angiofibromas, leading to the reduction in size and in the erythema and, in
some cases, to the complete resolution of the cutaneous lesions. However, the
long-term safety evidence is still scarce.<sup><xref ref-type="bibr" rid="r5">5</xref></sup> Early mTOR inhibition can prevent the development of facial
angiofibromas, as suggested by a case report in a female monozygotic twin treated
with systemic everolimus for SEGA since she was four years of age. Her twin sister
who was not treated developed facial angiofibromas when she was six years of age,
while the patient treated did not.<sup><xref ref-type="bibr" rid="r34">34</xref></sup></p>
<p>At last, it is known that many dermatological diseases cause a negative impact in the
life of patients, due to stigmas caused by the appearance of cutaneous lesions. This
not only affects their emotional state, but also their social relations and daily
activities. In TSC patients, we observe this impact, so it is fundamental that the
medical team that follows these patients to consider not only the clinical aspects
of the disease, but also the psychologic and social morbidities inherent to this
condition.<sup><xref ref-type="bibr" rid="r35">35</xref>,<xref ref-type="bibr" rid="r36">36</xref></sup></p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial support: None.</p>
</fn>
<fn fn-type="other" id="fn1">
<label>*</label>
<p>Work conducted at the Outpatient Clinic of Pediatric Dermatology, Department of
Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade
de São Paulo (HC-FMUSP), São Paulo (SP), Brazil.</p>
</fn>
<fn fn-type="COI-statement">
<p>Conflict of interests: None.</p>
</fn>
</fn-group>
<app-group>
<app id="app1">
<title>QUESTIONS</title>
<p>
<list list-type="order"><list-item><p>
<bold>Tuberous sclerosis complex is a genodermatosis:</bold>
</p><list list-type="alpha-upper"><list-item><p>Autosomal dominant with hamartomas that affect multiple
organs.</p></list-item><list-item><p>Autosomal recessive with hamartomas that affect multiple
organs.</p></list-item><list-item><p>Autosomal dominant predominantly affecting females, and the
most commonly affected organs are skin, central nervous
system, heart, lungs and kidneys.</p></list-item><list-item><p>Autosomal recessive with vascular malformations in many
organs, being the most affected skin and central nervous
system.</p></list-item></list></list-item><list-item><p>
<bold>The classical tuberous sclerosis triad is characterized
by:</bold>
</p><list list-type="alpha-upper"><list-item><p>Shagreen patch, facial angiofibromas and mental
retardation.</p></list-item><list-item><p>Epilepsy, sebaceous adenoma and shagreen patch.</p></list-item><list-item><p>Facial angiofibromas, fibrous cephalic plaque and
epilepsy.</p></list-item><list-item><p>Mental retardation, epilepsy and sebaceous adenoma
(angiofibroma).</p></list-item></list></list-item><list-item><p>
<bold>Choose the sentence with the correct sequence:</bold>
</p><list list-type="simple"><list-item><p>( ) Skin lesions are found in more than 90% of cases, the
majority appearing in the 3<sup>rd</sup> decade of life.</p></list-item><list-item><p>( ) “Ash-leaf” lesions tend to follow Blaschko lines when on
the trunk, typical for type 3 mosaicism.</p></list-item><list-item><p>( ) Hypopigmented macules in “confetti” or guttate leukoderma
are hypopigmented macules that appear over the years.</p></list-item><list-item><p>( ) Hypopigmented macules are many times found since birth,
allowing for the early diagnosis of the disease when
associated to other clinical findings.</p></list-item><list-item><list list-type="alpha-upper"><list-item><p>F T T F</p></list-item><list-item><p>F F F T</p></list-item><list-item><p>T T F T</p></list-item><list-item><p>F T F T</p></list-item></list></list-item></list></list-item><list-item><p>
<bold>About connective tissue nevi and ungual fibromas or Koenen
tumors, it is correct to say that:</bold>
</p><list list-type="alpha-lower"><list-item><p>Connective tissue nevi seen in TSC are normal-colored to
brown plaques restricted to the lumbosacral region.</p></list-item><list-item><p>Shagreen patch many times have the aspect of orange peel and
are found on the upper back.</p></list-item><list-item><p>Fibrous cephalic plaque is present in more than 80% of cases,
being most commonly found on one side of the forehead.</p></list-item><list-item><p>Koenen tumor usually appears during adolescence and has a
predilection for females and the toes.</p></list-item></list></list-item><list-item><p>
<bold>According to the systemic manifestations of TSC, we can affirm
that the correct items are:</bold>
</p><list list-type="order"><list-item><p>Angiomyolipomas increase progressively from infancy and stop
growing in the elderly.</p></list-item><list-item><p>Renal lesions have an indolent, clinically asymptomatic
course, with no potentially severe repercussions in the
patient’s life.</p></list-item><list-item><p>In cases of patients that evolve with hematuria in adulthood,
the possibility of malignant transformation of the
angiomyolipomas must be kept in mind, since they are usually
asymptomatic.</p></list-item><list-item><p>Lymphangioleiomyomatosis affects predominantly younger women
with the first manifestations after early adolescence.</p></list-item><list-item><p>Rhabdomyoma is the most common cardiac tumor and tends to
grow progressively in the first year, when it stabilizes and
continues until adulthood.</p></list-item><list-item><list list-type="alpha-upper"><list-item><p>1 - 3</p></list-item><list-item><p>2 - 4</p></list-item><list-item><p>3 - 5</p></list-item><list-item><p>1 - 4</p></list-item></list></list-item><list-item><p>
<bold>Choose the INCORRECT option:</bold>
</p><list list-type="alpha-upper"><list-item><p>The identification of the pathogenic TSC1 or TSC2 DNA
mutation is not enough to establish the diagnosis of
TSC.</p></list-item><list-item><p>Molecular testing yields a positive result in 75% to
90% of TSC patients.</p></list-item><list-item><p>In 10% to 25% of patients, conventional genetic
testing does not identify the pathogenic TSC1 or
TSC2 mutation.</p></list-item><list-item><p>The identification of the pathogenic mutation for TSC
in conventional genetic testing configures an
independent diagnostic criterion.</p></list-item></list></list-item></list></list-item><list-item><p>
<bold>About the diagnostic criteria for the tuberous sclerosis
complex, reviewed in 2012, in the second International Tuberous
Sclerosis Complex Consensus Conference, all are included as
extracutaneous manifestations, EXCEPT:</bold>
</p><list list-type="alpha-upper"><list-item><p>Subependymal giant cell astrocytoma.</p></list-item><list-item><p>Cardiac rhabdomyoma.</p></list-item><list-item><p>Lymphangioleiomyomatosis.</p></list-item><list-item><p>Pigmented hamartomas of the iris.</p></list-item></list></list-item><list-item><p>
<bold>It is a MAJOR clinical criterion for the diagnosis of
TSC:</bold>
</p><list list-type="alpha-upper"><list-item><p>≥ 5 hypopigmented macules with at least 3mm
diameter.</p></list-item><list-item><p>≥ 3 facial angiofibromas.</p></list-item><list-item><p>≥ 2 intraoral fibromas.</p></list-item><list-item><p>&gt; 3 dental enamel pits.</p></list-item></list></list-item><list-item><p>
<bold>From the dermatological point of view, many destructive or
surgical treatment options are used to reduce the development of
and remove facial angiofibromas. It is correct to say
that:</bold>
</p><list list-type="alpha-upper"><list-item><p>The destructive procedures are usually comfortable for the
patient and can be performed at any age.</p></list-item><list-item><p>It usually is not necessary to repeat laser treatments
periodically because the lesions tend not to recur.</p></list-item><list-item><p>Are therapeutic options for facial angiofibromas
dermabrasion, surgical excision, electrocautery and
laser.</p></list-item><list-item><p>It is not necessary to combine therapeutic methods to
optimize results since that regardless of the treatment
chosen, all provide satisfactory results.</p></list-item></list></list-item><list-item><p>
<bold>Diagnostic suspicion of TSC comes from the following findings,
EXCEPT:</bold>
</p><list list-type="alpha-upper"><list-item><p>Antenatal detection of cardiac rhabdomyomas.</p></list-item><list-item><p>Post-natal identification of hypopigmented patches on the
skin.</p></list-item><list-item><p>Visualization of ephelis on the axillary or inguinal
regions.</p></list-item><list-item><p>Seizures in childhood, particularly with spasms.</p></list-item></list></list-item></list>
</p>
</app>
</app-group>
<ref-list>
<title>REFERENCES</title>
<ref id="r1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>IMC</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex</article-title>
<source/>An Bras Dermatol
          <year>2012</year>
<volume>87</volume>
<fpage>184</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">22570021</pub-id>
</element-citation>
</ref>
<ref id="r2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinton</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Romp</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Knilans</surname>
<given-names>TK</given-names>
</name>
<collab>International Tuberous Sclerosis Consensus Group</collab>
</person-group>
<article-title>Cardiovascular manifestations of tuberous sclerosis complex and
summary of the revised diagnostic criteria and surveillance and management
recommendations from the International Tuberous Sclerosis Consensus
Group</article-title>
<source/>J Am Heart Assoc
          <year>2014</year>
<volume>3</volume>
<elocation-id>e001493</elocation-id>
<pub-id pub-id-type="pmid">25424575</pub-id>
</element-citation>
</ref>
<ref id="r3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<collab>International Tuberous Sclerosis Complex Consensus Group</collab>
</person-group>
<article-title>Tuberous sclerosis complex diagnostic criteria update:
recommendations of the 2012 International Tuberous Sclerosis Complex
Consensus Conference</article-title>
<source/>Pediatr Neurol
          <year>2013</year>
<month>10</month>
<volume>49</volume>
<issue>4</issue>
<fpage>243</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="pmid">24053982</pub-id>
</element-citation>
</ref>
<ref id="r4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadowski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kotulska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Józwiak</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Systemic effects of treatment with mTOR inhibitors in tuberous
sclerosis complex: a comprehensive review</article-title>
<source/>J Eur Acad Dermatol Venereol
          <year>2016</year>
<volume>30</volume>
<fpage>586</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="pmid">26403211</pub-id>
</element-citation>
</ref>
<ref id="r5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiMario Jr</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ebrahimi-Fakhari</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Tuberous SclerosisComplex</article-title>
<source/>Pediatr Clin North Am
          <year>2015</year>
<volume>62</volume>
<fpage>633</fpage>
<lpage>648</lpage>
<pub-id pub-id-type="pmid">26022167</pub-id>
</element-citation>
</ref>
<ref id="r6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacks</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Witman</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Tuberous Sclerosis Complex: An Update for
Dermatologists</article-title>
<source/>Pediatr Dermatol
          <year>2015</year>
<volume>32</volume>
<fpage>563</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="pmid">25776100</pub-id>
</element-citation>
</ref>
<ref id="r7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacKeigan</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Differentiating the mTOR inhibitors everolimus and sirolimus in
the treatment of tuberous sclerosis complex</article-title>
<source/>Neuro Oncol
          <year>2015</year>
<volume>17</volume>
<fpage>1550</fpage>
<lpage>1559</lpage>
<pub-id pub-id-type="pmid">26289591</pub-id>
</element-citation>
</ref>
<ref id="r8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Annual review of children with tuberous sclerosis</article-title>
<source/>Arch Dis Child Educ Pract Ed
          <year>2015</year>
<volume>100</volume>
<fpage>114</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="pmid">25112285</pub-id>
</element-citation>
</ref>
<ref id="r9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Au</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Roach</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Batchelor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sparagana</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Delgado</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genotype/phenotype correlation in 325 individuals referred for a
diagnosis of tuberous sclerosis complex in the United States</article-title>
<source/>Genet Med
          <year>2007</year>
<volume>9</volume>
<fpage>88</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">17304050</pub-id>
</element-citation>
</ref>
<ref id="r10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Almoazen</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A novel topical rapamycin cream for the treatment of facial
angiofibromas in tuberous sclerosis complex</article-title>
<source/>J Child Neurol
          <year>2013</year>
<volume>28</volume>
<fpage>933</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="pmid">23680945</pub-id>
</element-citation>
</ref>
<ref id="r11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haemel</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>O'Brian</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Topical rapamycin: a novel approach to facial angiofibromas in
tuberous sclerosis</article-title>
<source/>Arch Dermatol
          <year>2010</year>
<volume>146</volume>
<fpage>715</fpage>
<lpage>718</lpage>
<pub-id pub-id-type="pmid">20644030</pub-id>
</element-citation>
</ref>
<ref id="r12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balestri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Patrizi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Angileri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Magnano</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Analysis of current data on the use of topical rapamycin in the
treatment of facial angiofibromas in tuberous sclerosis
complex</article-title>
<source/>J Eur Acad Dermatol Venereol
          <year>2015</year>
<volume>29</volume>
<fpage>14</fpage>
<lpage>20</lpage>
</element-citation>
</ref>
<ref id="r13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koenig</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Roberson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Samuels</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Slopis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Woerner</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Topical rapamycin therapy to alleviate the cutaneous
manifestations of tuberous sclerosis complex: a double-blind, randomized,
controlled trial to evaluate the safety and efficacy of topically applied
rapamycin</article-title>
<source/>Drugs R D
          <year>2012</year>
<volume>12</volume>
<fpage>121</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">22934754</pub-id>
</element-citation>
</ref>
<ref id="r14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valerón-Almazán</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vitiello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abuchar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kerdel</surname>
<given-names>FA</given-names>
</name>
</person-group>
<article-title>Topical rapamycin solution to treat multiple facial angiofibromas
in a patient with tuberous sclerosis</article-title>
<source/>Actas Dermosifiliogr
          <year>2012</year>
<volume>103</volume>
<fpage>165</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">21861956</pub-id>
</element-citation>
</ref>
<ref id="r15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bruzzi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Fladrowski</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hertzberg</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TOSCA - first international registry to address knowledge gaps in
the natural history and management of tuberous sclerosis
complex</article-title>
<source/>Orphanet J Rare Dis
          <year>2014</year>
<volume>9</volume>
<fpage>182</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="pmid">25424195</pub-id>
</element-citation>
</ref>
<ref id="r16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatt</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>PO</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Finelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Manickavachagam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Legere</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Natural History of Renal Angiomyolipoma (AML): Most Patients with
Large AMLs &amp;gt; 4cm Can Be Offered Active Surveillance as an Initial
Management Strategy</article-title>
<source/>Eur Urol
          <year>2016</year>
<volume>70</volume>
<fpage>85</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">26873836</pub-id>
</element-citation>
</ref>
<ref id="r17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Nijmeh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Henske</surname>
<given-names>EP</given-names>
</name>
</person-group>
<article-title>New developments in the genetics and pathogenesis of tumours in
tuberous sclerosis complex</article-title>
<source/>J Pathol
          <year>2017</year>
<volume>241</volume>
<fpage>219</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">27753446</pub-id>
</element-citation>
</ref>
<ref id="r18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakkar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vallonthaiel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bora</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seth</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Composite renal cell carcinoma and angiomyolipoma in a patient
with Tuberous sclerosis: A diagnostic dilema</article-title>
<source/>Can Urol Assoc J
          <year>2015</year>
<volume>9</volume>
<fpage>E507</fpage>
<lpage>E510</lpage>
<pub-id pub-id-type="pmid">26279726</pub-id>
</element-citation>
</ref>
<ref id="r19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moavero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Neurological and neuropsychiatric aspects of tuberous sclerosis
complex</article-title>
<source/>Lancet Neurol
          <year>2015</year>
<volume>14</volume>
<fpage>733</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="pmid">26067126</pub-id>
</element-citation>
</ref>
<ref id="r20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex: a roadmap for future
research</article-title>
<source/>Pediatr Neurol Briefs
          <year>2016</year>
<volume>30</volume>
<fpage>32</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">27617567</pub-id>
</element-citation>
</ref>
<ref id="r21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
<collab>International Tuberous Sclerosis Complex Consensus Group</collab>
</person-group>
<article-title>Tuberous sclerosis complex surveillance and management:
recommendations of the 2012 International Tuberous Sclerosis Complex
Consensus Conference</article-title>
<source/>Pediatr Neurol
          <year>2013</year>
<fpage>49255</fpage>
<lpage>49265</lpage>
</element-citation>
</ref>
<ref id="r22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Geronemus</surname>
<given-names>RG</given-names>
</name>
</person-group>
<article-title>New Technique Using Combined Pulsed Dye Laser and Fractional
Resurfacing for Treating Facial Angiofibromas in Tuberous
Sclerosis</article-title>
<source/>Lasers Surg Med
          <year>2010</year>
<volume>42</volume>
<fpage>357</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">20583249</pub-id>
</element-citation>
</ref>
<ref id="r23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Komurasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Billings</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mesenchymal-epithelial interactions involving epiregulin in
tuberous sclerosis complex hamaratomas</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2008</year>
<volume>105</volume>
<fpage>3539</fpage>
<lpage>3544</lpage>
<pub-id pub-id-type="pmid">18292222</pub-id>
</element-citation>
</ref>
<ref id="r24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>McCartney</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>AL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sirolimus therapy for angiomyolipoma in tuberous sclerosis and
sporadic lymphangioleiomyomatosis: a phase 2 trial</article-title>
<source/>Clin Cancer Res
          <year>2011</year>
<volume>17</volume>
<fpage>4071</fpage>
<lpage>4081</lpage>
<pub-id pub-id-type="pmid">21525172</pub-id>
</element-citation>
</ref>
<ref id="r25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Care</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Holland-Bouley</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Everolimus for subependymal giant cell astrocytoma: 5-year final
analysis</article-title>
<source/>Ann Neurol
          <year>2015</year>
<volume>78</volume>
<fpage>929</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="pmid">26381530</pub-id>
</element-citation>
</ref>
<ref id="r26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Yapici</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Polster</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nabbout</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjunctive everolimus therapy for treatment-resistant focal-onset
seizures associated with tuberous sclerosis (EXIST-3): a phase 3,
randomised, double-blind, placebo-controlled study</article-title>
<source/>Lancet
          <year>2016</year>
<volume>388</volume>
<fpage>2153</fpage>
<lpage>2163</lpage>
<pub-id pub-id-type="pmid">27613521</pub-id>
</element-citation>
</ref>
<ref id="r27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sparagana</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bebin</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuperman</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy and safety of everolimus for subependymal giant cell
astrocytomas associated with tuberous sclerosis complex (EXIST-1): a
multicentre, randomised, placebo-controlled phase 3 trial</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>125</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">23158522</pub-id>
</element-citation>
</ref>
<ref id="r28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bissler</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Radzikowska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Everolimus for angiomyolipoma associated with tuberous sclerosis
complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre,
randomised, double-blind, placebo-controlled trial</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>817</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="pmid">23312829</pub-id>
</element-citation>
</ref>
<ref id="r29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>d'Augères</surname>
<given-names>GB.</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>JC.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Castellana</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tuberous Sclerosis registry to increase disease Awareness (TOSCA)
- baseline data on 2093 patients</article-title>
<source/>Orphanet J Rare Dis
          <year>2017</year>
<volume>12</volume>
<fpage>2</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">28057044</pub-id>
</element-citation>
</ref>
<ref id="r30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotulska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chmielewski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Borkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jurkiewicz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kuczynski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kmiec</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term effect of everolimus on epilepsy and growth in children
under 3 years of age treated for subependymal giant cell astrocytoma
associated with tuberous sclerosis complex</article-title>
<source/>Eur J Paediatr Neurol
          <year>2013</year>
<volume>17</volume>
<fpage>479</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="pmid">23567018</pub-id>
</element-citation>
</ref>
<ref id="r31">
<label>31</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>Anvisa.gov.br [Internet]</collab>
</person-group>
<source/>Afinitor. Drug leaflet
          <publisher-loc>Suíça</publisher-loc>
<publisher-name>Novartis Pharma Stein AG</publisher-name>
<date-in-citation content-type="access-date">2018 Mar 14</date-in-citation>
<comment>Available in: <ext-link ext-link-type="uri" xlink:href="http://anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=6303092015&amp;pIdAnexo=2744450">http://anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=6303092015&amp;pIdAnexo=2744450</ext-link></comment>
</element-citation>
</ref>
<ref id="r32">
<label>32</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>Anvisa.gov.br [Internet]</collab>
</person-group>
<source/>Rapamune. Drug leaflet
          <publisher-loc>Irlanda</publisher-loc>
<publisher-name>Pfizer Ireland Pharmaceuticals</publisher-name>
<date-in-citation content-type="access-date">2018 Mar 14</date-in-citation>
<comment>Available in: <ext-link ext-link-type="uri" xlink:href="http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=11519742017&amp;pIdAnexo=7326672">http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=11519742017&amp;pIdAnexo=7326672</ext-link></comment>
</element-citation>
</ref>
<ref id="r33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nathan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cowen</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Haughey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improvement of tuberous sclerosis complex skin tumors during
long-term treatment with oral sirolimus</article-title>
<source/>J Am Acad Dermatol
          <year>2015</year>
<fpage>73802</fpage>
<lpage>73808</lpage>
</element-citation>
</ref>
<ref id="r34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bissler</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Optimal treatment of tuberous sclerosis complex associated renal
angiomyolipomata: a systematic review</article-title>
<source/>Ther Adv Urol
          <year>2016</year>
<volume>8</volume>
<fpage>279</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="pmid">27928430</pub-id>
</element-citation>
</ref>
<ref id="r35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Switon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kotulska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Janusz-Kaminska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zmorzynska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jaworski</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tuberous Sclerosis Complex: From Molecular Biology to Novel
Therapeutic Approaches</article-title>
<source/>IUBMB Life
          <year>2016</year>
<volume>68</volume>
<fpage>955</fpage>
<lpage>962</lpage>
<pub-id pub-id-type="pmid">27797139</pub-id>
</element-citation>
</ref>
<ref id="r36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotulska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Borkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Possible prevention of tuberous sclerosis complex
lesions</article-title>
<source/>Pediatrics
          <year>2013</year>
<volume>132</volume>
<fpage>e239</fpage>
<lpage>e242</lpage>
<pub-id pub-id-type="pmid">23733802</pub-id>
</element-citation>
</ref>
<ref id="r37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Lorenzini</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reinehr</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Lovato</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Assessment of the quality of life of pediatric patients at a
center of excellence in dermatology in southern Brazil</article-title>
<source/>An Bras Dermatol
          <year>2012</year>
<volume>87</volume>
<fpage>697</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="pmid">23044560</pub-id>
</element-citation>
</ref>
<ref id="r38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taborda</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>KAM</given-names>
</name>
<name>
<surname>Lisboa</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Welter</surname>
<given-names>EQ</given-names>
</name>
</person-group>
<article-title>Evaluation of the quality of life and psychological distress of
patients with different dermatoses in a dermatology referral center in
southern Brazil</article-title>
<source/>An Bras Dermatol
          <year>2010</year>
<volume>85</volume>
<fpage>52</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">20464087</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="t2" orientation="portrait" position="float">
<table frame="box" rules="groups">
<colgroup span="1">
<col span="1" width="20%"/>
<col span="1" width="20%"/>
<col span="1" width="20%"/>
<col span="1" width="20%"/>
<col span="1" width="20%"/>
</colgroup>
<tbody>
<tr>
<td align="left" colspan="5" rowspan="1">
<bold>Answer key</bold>
</td>
</tr>
<tr style="border-bottom-width:thin;border-bottom-style:solid">
<td align="left" colspan="5" rowspan="1">Gnathostomiasis: an emerging infectious disease
relevant to all dermatologists. An Bras Dermatol. 2018;93(2):
172-80.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>1. D</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>3. A</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>5. D</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>7. D</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>9. D</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold>2. C</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>4. A</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>6. C</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>8. B</bold>
</td>
<td align="center" colspan="1" rowspan="1">
<bold>10. D</bold>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="t3" orientation="portrait" position="float">
<table frame="void" rules="none">
<colgroup span="1">
<col span="1" width="100%"/>
</colgroup>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1" style="background-color:#a071a1;color:#ffffff"><bold>Papers</bold><break></break>    Information for all members: The
EMC-D questionnaire is now available at the homepage of the Brazilian
Annals of Dermatology: www.anaisdedermatologia.org.br. The deadline for
completing the questionnaire is 30 days from the date of online
publication.</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>